Genocea Biosciences (GNCA) Short Interest Ratio & Short Volume

Short interest is the volume of Genocea Biosciences shares that have been sold short but have not yet been closed out or covered. As of May 31st, investors have sold 3,590,000 shares of GNCA short. 13.58% of Genocea Biosciences' shares are currently sold short. Learn More on Genocea Biosciences' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 13.58% of Genocea Biosciences' floating shares are currently sold short.

Genocea Biosciences saw a increase in short interest in May. As of May 31st, there was short interest totaling 3,590,000 shares, an increase of 118.9% from the previous total of 1,640,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Genocea Biosciences currently has issued a total of 58,730,000 shares. Some of Genocea Biosciences' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Genocea Biosciences currently has a public float of 26,440,000 shares.

13.58% of Genocea Biosciences' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Genocea Biosciences: Bruush Oral Care Inc. (62.06%), Acorda Therapeutics, Inc. (0.66%), Scinai Immunotherapeutics Ltd. (0.29%), TC Biopharm (Holdings) Plc (30.07%), Windtree Therapeutics, Inc. (0.54%), Gamida Cell Ltd. (7.11%), Avalon GloboCare Corp. (1.74%), TRACON Pharmaceuticals, Inc. (32.67%), Finch Therapeutics Group, Inc. (1.70%), Palisade Bio, Inc. (0.21%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.12 billion), Palo Alto Networks, Inc. ($3.85 billion), Lucid Group, Inc. ($2.66 billion), HP Inc. ($2.31 billion), Coinbase Global, Inc. ($2.14 billion), GameStop Corp. ($1.94 billion), T. Rowe Price Group, Inc. ($1.91 billion), Chesapeake Energy Co. ($1.79 billion), Rivian Automotive, Inc. ($1.62 billion), and Carnival Co. & plc ($1.59 billion). View all of the most shorted stocks.

Short selling GNCA is an investing strategy that aims to generate trading profit from Genocea Biosciences as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Genocea Biosciences occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of GNCA, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GNCA, twice per month. The most recent reporting period available is May, 31 2022.